The SC formulation of Orencia is a fixed 125mg dose which can be given weekly through an injection under the skin following a single IV loading dose of approximately 10mg/kg.
In a trial, Orencia SC showed similar safety and efficacy to Orencia IV.
BMS Commercial Operations senior vice president and US, Japan and Intercontinental president Anthony Hooper said the continued development of Orencia exemplifies their focus on areas of serious diseases and biologics drug development.